Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3Classical hematology 1

Conditions

Arthritis, Rheumatoid 10Psoriasis 6Leukemia 5Lymphoma, Follicular 4Myelodysplastic Syndromes 3Inflammation 3Asthma 3Arthritis, Juvenile 3Vasculitis 2Uveitis 2Respiratory Distress Syndrome 2Recurrence 2Prostatic Neoplasms 2Pneumonia 2Neuroblastoma 2Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic-Myeloproliferative Diseases 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Granulomatosis with Polyangiitis 2Bronchiolitis Obliterans 2Wilms Tumor 1Temporomandibular Joint Disorders 1Stomatitis 1Spondylitis, Ankylosing 1Spondylarthritis 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1

Interventions

Cyclophosphamide 209fludarabine phosphate 184Azacitidine 159fludarabine 142Busulfan 138Tacrolimus 119Mycophenolic Acid 111Cytarabine 110Whole-Body Irradiation 106Peripheral Blood Stem Cell Transplantation 98Antilymphocyte Serum 97Melphalan 90Filgrastim 87Cyclosporine 83Decitabine 82Methotrexate 79venetoclax 63Granulocyte Colony-Stimulating Factor 56Radiotherapy 49Stem Cell Transplantation 48Thiotepa 47Cord Blood Stem Cell Transplantation 42Clofarabine 42thymoglobulin 41Specimen Handling 35Etoposide 35Methylprednisolone 34Sirolimus 33Injections 27Biopsy 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Myelodysplastic Syndromes × Etanercept × Clear all
NCT00093366 2011-11-30

Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

Phase 1/2 Completed
32 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00217386 2010-09-15

Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes

Fred Hutchinson Cancer Center

Phase 2 Completed
30 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT00005853 2010-04-02

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

Fred Hutchinson Cancer Center

Phase 2 Completed
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡